10-K/A: AnaptysBio Files 10-K/A Amendment, Updates Governance and Compensation

AnaptysBio amends its 2025 annual report to include details on board composition changes, executive compensation, and related party transactions.

Summary

• This filing is an amendment (10-K/A) to AnaptysBio, Inc.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
• The amendment is filed to include information required by Items 9B, 10, 11, 12, 13, and 14 of Form 10-K, as a definitive proxy statement will not be filed within 120 days of the fiscal year-end.
• Key updates include changes to the Board of Directors' class apportionment following the departure of four members on April 27, 2026.
• Detailed information on directors' backgrounds, committee memberships (Audit, Compensation, Nominating and Corporate Governance), and their independence is provided.
• The filing outlines executive compensation for 2025, including base salaries, annual cash bonuses, and long-term incentive compensation (stock options and RSUs).
• It details the 2025 corporate performance goals used for bonus calculations, which were achieved at 110% of target.
• Information on outstanding equity awards as of December 31, 2025, for named executive officers (NEOs) is presented.
• The impact of the April 20, 2026, spin-off of First Tracks Biotherapeutics, Inc. on executive officers and compensation arrangements is explained, noting Daniel Faga as the sole remaining executive officer.
• Details on security ownership by directors, executive officers, and major shareholders as of April 1, 2026, are included.
• The company's related party transaction policy and director independence standards are reiterated.
• Fees paid to the principal accounting firm, KPMG LLP, for fiscal years 2025 and 2024 are disclosed.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the disclosure of a net loss and negative TSR, despite positive aspects in governance and compensation alignment.

Positives

• The company has a clear separation between the CEO and Chairman of the Board roles, promoting accountability and independent oversight.
• AnaptysBio maintains a Code of Conduct and Ethics applicable to all employees, officers, and directors.
• An Insider Trading Policy is in place, prohibiting hedging and pledging of company securities by employees, officers, and directors.
• The compensation committee retains an independent compensation consultant (Alpine Rewards) to ensure competitive and appropriate executive and director compensation.
• A significant portion of executive compensation is 'at-risk' and tied to corporate performance and stock price, aligning executive and stockholder interests.
• The company achieved 110% of its target corporate goals for 2025, leading to bonus payouts.
• The Board of Directors is composed of a majority of independent directors, meeting Nasdaq listing standards.
• All services provided by the independent auditor, KPMG LLP, were pre-approved by the Audit Committee.

Negatives

• The company experienced the departure of four board members on April 27, 2026, necessitating an update to the Board's class apportionment.
• The company's net income for 2025 was a loss of $13,232,000.
• The total shareholder return (TSR) for 2025 was negative, indicated by a $100 investment being worth only $156, a significant decrease from prior years.
• Two executive officers, Paul Lizzul and Dennis Mulroy, ceased employment with the company in connection with the spin-off of First Tracks Biotherapeutics.
• The company is a smaller reporting company and not required to provide a Compensation Discussion and Analysis, though it elected to provide additional narrative disclosure.

Risks

• The company's business is subject to the inherent risks of biotechnology development, including regulatory approval processes and clinical trial outcomes.
• The departure of four board members could potentially impact board dynamics and oversight, although the classes were re-apportioned.
• The company's financial statements reflect a net loss, indicating ongoing investment and development phases.
• The negative total shareholder return in 2025 highlights market concerns or underperformance relative to the broader market.

Future Outlook

The filing does not contain specific forward-looking financial guidance. However, it details the ongoing compensation structures and board composition, which are foundational elements for future strategic execution. The spin-off of First Tracks Biotherapeutics suggests a strategic shift in focus for AnaptysBio.

Management Comments

• Daniel Faga (President and Chief Executive Officer) certified that the report does not contain untrue material facts and fairly presents financial condition, results of operations, and cash flows.
• Management emphasizes a pay-for-performance philosophy, linking a significant portion of executive compensation to corporate performance and stockholder value.
• The company values stockholder opinion, noting that approximately 73% of votes approved its executive compensation program at the 2025 Annual Meeting.

Industry Context

StockSavvy.ai notes that AnaptysBio's filing reflects typical disclosures for a biotechnology company at its stage, particularly concerning executive compensation, board governance, and strategic restructuring like spin-offs. The focus on equity-based compensation and performance metrics is standard for attracting and retaining talent in this competitive sector.

Comparison to Industry Standards

• The compensation peer group for 2025 included companies like Allogene Therapeutics, Centessa Pharmaceuticals, Kura Oncology, and Replimune Group, indicating AnaptysBio's positioning among similarly sized and staged biotechnology firms.
• The use of stock options and RSUs as primary long-term incentive vehicles is a common practice across the biotechnology industry.
• The structure of the Board of Directors into three classes with staggered terms is a widely adopted corporate governance practice in the US.
• The company's focus on clinical development programs (ANB033, rosnilimab, ANB101) aligns with industry trends in seeking novel therapeutics for unmet medical needs.

Management Changes

Corporate Governance

Related Party Transactions

• The filing states there have been no transactions requiring disclosure under the related party transactions policy since January 1, 2023, other than those covered under Executive Compensation.
• The company has a written policy requiring review and approval by the audit committee for related party transactions exceeding $120,000 or 1% of average total assets.

Stakeholder Impact

• Shareholders: The spin-off may impact the strategic focus and future value of AnaptysBio shares. The negative TSR in 2025 indicates potential shareholder dissatisfaction with recent performance.
• Employees: The spin-off resulted in the departure of two executive officers. Compensation structures are designed to align executive interests with stockholders.
• Management: Executive compensation is tied to corporate performance, with a significant portion at-risk, aligning their incentives with company success.
• Directors: Board composition was updated, and director independence is maintained according to Nasdaq and SEC standards.

Next Steps

• The company will continue to operate with Daniel Faga as the sole executive officer following the spin-off.
• The Board of Directors will continue to oversee the company's strategy and risk management.
• The company will hold its 2026 Annual Meeting of Stockholders, including a Say-on-Pay vote.
• The company's audit committee will oversee the audit of financial statements for the fiscal year ending December 31, 2026, by KPMG LLP.

Key Dates

Recommendation

The filing is an amendment to an annual report, primarily updating governance and compensation details rather than presenting new financial performance. While the company has a solid governance structure and aligns executive pay with performance, the disclosed net loss and negative TSR for 2025 suggest caution. The strategic spin-off could be positive long-term, but immediate catalysts for significant share price appreciation are not evident in this amendment.

Keywords

AnaptysBio, 10-K/A, Amendment, Annual Report, Corporate Governance, Executive Compensation, Board of Directors, Stock Options, Restricted Stock Units, Spin-Off, First Tracks Biotherapeutics, SEC Filing, Biotechnology